Add The Wire As Your Trusted Source
For the best experience, open
https://m.thewire.in
on your mobile browser.
AdvertisementAdvertisement

Helped By Base Effect, India's GDP Growth Accelerates to 20.1% in Q1 FY'22

India's GVA growth in Q1 FY’22 was at 18.8%.
India's GVA growth in Q1 FY’22 was at 18.8%.
helped by base effect  india s gdp growth accelerates to 20 1  in q1 fy 22
Representative image. Photo: Reuters/Anushree Fadnavis/File photo
Advertisement

New Delhi: The Indian economy grew at a record pace in the April-June 2021 quarter, compared to the same quarter last year, which is when the country was in the midst of an unprecedented national lockdown due to the COVID-19 pandemic.

According to government data released on Tuesday (August 31) evening, GDP in Q1 FY'22 rose by 20.1% aided by the low base last year, while GVA growth in Q1 FY’22 was at 18.8%.

In the January-March quarter, GDP rose by 1.6%, while GVA rose by 3.7%.

India’s GDP at constant prices (2011-12) in the first quarter stood at Rs 32.38 lakh crore -- which is still lower than the Rs 35.35 lakh crore seen in the first quarter of 2019-20, signaling that the country is yet to fully emerge from the Covid-induced slump.

Advertisement

Median estimates of 23 economists polled by Bloomberg had projected GDP to rise by 21% in the first quarter, while GVA is expected to rise by 19.3%.

"GDP at Constant (2011-12) Prices in Q1 of 2021-22 is estimated at Rs 32.38 lakh crore, as against Rs 26.95 lakh crore in Q1 of 2020-21, showing a growth of 20.1 percent as compared to contraction of 24.4% in Q1 2020-21. Quarterly GVA at Basic Price at Constant (2011-12) Prices for Q1 of 2021-22 is estimated at Rs 30.48 lakh crore, as against Rs 25.66 lakh crore in Q1 of 2020-21, showing a growth of 18.8%," said Ministry of Statistics & Programme Implementation in a statement.

Advertisement

This article went live on August thirty-first, two thousand twenty one, at four minutes past six in the evening.

The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.

Advertisement
Advertisement
tlbr_img1 Series tlbr_img2 Columns tlbr_img3 Multimedia